AOU Careggi

Running trials

• Recruiting

  A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

  NCT07154745· Phase 3· Source

• Not yet recruiting

  Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma

  NCT07460245· Phase 2· Source

• Recruiting

  Nerve-SPARing Robotic Prostatectomy: The Impact of Patient Baseline Profiles on Erectile Function

  NCT07747272· Source

• Recruiting

  Landiolol in Mitral Valve Surgery

  NCT06793670· Phase 4· Source

• Recruiting

  FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

  NCT06733038· Phase 3· Source

• Recruiting

  Assessment of Infection Activity in Travelers and Migrants Diagnosed With Chronic Schistosomiasis

  NCT06873308· Source

• Recruiting

  Master Framework For Relapse or Refractory Acute Myeloid Leukemia

  NCT06459024· Source

• Recruiting

  A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced

  NCT06467383· Source

• Active, not recruiting

  A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

  NCT05993234· Source

• Active, not recruiting

  A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

  NCT06054555· Phase 3· Source

• Active, not recruiting

  An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

  NCT05876754· Phase 3· Source

• Recruiting

  A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

  NCT05744921· Phase 3· Source

• Active, not recruiting

  VIATORR Device Registry

  NCT05661331· Source

• Active, not recruiting

  An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

  NCT05363319· Source

• Active, not recruiting

  A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment

  NCT05133531· Phase 3· Source

• Recruiting

  Sarcoma Preoperative Radiation With Simultaneous INTegrated Boost (SPRINT)

  NCT05761054· Source

• Active, not recruiting

  A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

  NCT05049798· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukemia1 recruiting
• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Heart failure1 recruiting
• Lung cancer1 recruiting
• Prostate cancer1 recruiting
• Sarcoma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

  NCT06285318· Source

• Completed

  AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study

  NCT05028660· Source

• Completed

  A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag

  NCT04567602· Source

• Completed

  Atezolizumab Trial in Endometrial Cancer - AtTEnd

  NCT03603184· Phase 3· Source

• Completed

  Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

  NCT03250338· Phase 3· Source